Protagonist Therapeutics (NASDAQ:PTGX) and Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) Critical Survey

Protagonist Therapeutics (NASDAQ:PTGX) and Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) are both mid-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, profitability, risk, valuation, dividends and earnings.

Risk & Volatility

Protagonist Therapeutics has a beta of 1.53, suggesting that its share price is 53% more volatile than the S&P 500. Comparatively, Lakefront Biotherapeutics American Depositary Shares has a beta of 0.24, suggesting that its share price is 76% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent ratings for Protagonist Therapeutics and Lakefront Biotherapeutics American Depositary Shares, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Protagonist Therapeutics	0	0	16	2	3.11
Lakefront Biotherapeutics American Depositary Shares	0	5	3	0	2.38

Protagonist Therapeutics presently has a consensus price target of $158.19, indicating a potential upside of 13.48%. Lakefront Biotherapeutics American Depositary Shares has a consensus price target of $35.50, indicating a potential upside of 13.06%. Given Protagonist Therapeutics’ stronger consensus rating and higher probable upside, research analysts plainly believe Protagonist Therapeutics is more favorable than Lakefront Biotherapeutics American Depositary Shares.

Profitability

This table compares Protagonist Therapeutics and Lakefront Biotherapeutics American Depositary Shares’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Protagonist Therapeutics	29.40%	12.03%	11.23%
Lakefront Biotherapeutics American Depositary Shares	N/A	N/A	N/A

Institutional & Insider Ownership

98.6% of Protagonist Therapeutics shares are owned by institutional investors. Comparatively, 32.5% of Lakefront Biotherapeutics American Depositary Shares shares are owned by institutional investors. 5.2% of Protagonist Therapeutics shares are owned by company insiders. Comparatively, 2.9% of Lakefront Biotherapeutics American Depositary Shares shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Earnings & Valuation

This table compares Protagonist Therapeutics and Lakefront Biotherapeutics American Depositary Shares”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Protagonist Therapeutics	$46.02 million	196.01	-$130.15 million	$1.03	135.34
Lakefront Biotherapeutics American Depositary Shares	$1.26 billion	1.64	$363.05 million	($1.41)	-22.27

Lakefront Biotherapeutics American Depositary Shares has higher revenue and earnings than Protagonist Therapeutics. Lakefront Biotherapeutics American Depositary Shares is trading at a lower price-to-earnings ratio than Protagonist Therapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

Protagonist Therapeutics beats Lakefront Biotherapeutics American Depositary Shares on 13 of the 15 factors compared between the two stocks.

About Protagonist Therapeutics

Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company has a license and collaboration agreement with Takeda to commercialize rusfertide; and JNJ Innovative Medicines to co-develop Interleukin-23 receptor antagonist compound JNJ-2113. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.

About Lakefront Biotherapeutics American Depositary Shares

Galapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of various medicines for high unmet medical need. Its pipeline products include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn’s disease, ulcerative colitis, small bowel CD, fistulizing CD, ankylosing spondylitis, psoriatic arthritis, and uveitis. The company’s pipeline products also comprise GLPG1972 that has completed Phase 2b trial for treating osteoarthritis; Toledo molecules, including GLPG3970, GLPG4399, and GLPG4876 for inflammation; and GLPG4716 and Ziritaxestat to treat idiopathic pulmonary fibrosis. In addition, its other pipeline products include GLPG2737, a cystic fibrosis transmembrane conductance regulator that is in Phase 2 clinical trials to treat patients with autosomal dominant polycystic kidney disease; and GLPG0555, a JAK1 inhibitor, which is in Phase 1b for treatment of patients with osteoarthritis. The company has collaboration agreements with Gilead Sciences, Inc.; AbbVie S.à r.l.; and Novartis Pharma AG. Galapagos NV was incorporated in 1999 and is headquartered in Mechelen, Belgium.